.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The LIBERTY randomized phase 3b trial evaluated erenumab in people with episodic migraine who had already failed two to four preventive treatments because of inadequate efficacy or tolerability. Participants received erenumab 140 mg or placebo for 12 weeks. A clinically important proportion of previously difficult-to-treat patients achieved at least a 50% reduction in monthly migraine days, and the treatment was superior to placebo on several patient-reported outcomes. The trial is significant because many earlier preventive studies enrolled patients without the same degree of treatment failure. LIBERTY therefore supports CGRP-pathway therapy as an option for patients whose migraine remains frequent despite conventional preventive approaches. For HCPs, the practical implication is that a history of preventive failure does not mean that meaningful improvement is unattainable. Treatment choice should still consider comorbidity, reproductive issues, medication overuse and patient preference. The study also illustrates the value of trials that reflect treatment-refractory clinical populations rather than only newly diagnosed patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The LIBERTY randomized phase 3b trial evaluated erenumab in people with episodic migraine who had already failed two to four preventive treatments because of inadequate efficacy or tolerability. Participants received erenumab 140 mg or placebo for 12 weeks. A clinically important proportion of previously difficult-to-treat patients achieved at least a 50% reduction in monthly migraine days, and the treatment was superior to placebo on several patient-reported outcomes. The trial is significant because many earlier preventive studies enrolled patients without the same degree of treatment failure. LIBERTY therefore supports CGRP-pathway therapy as an option for patients whose migraine remains frequent despite conventional preventive approaches. For HCPs, the practical implication is that a history of preventive failure does not mean that meaningful improvement is unattainable. Treatment choice should still consider comorbidity, reproductive issues, medication overuse and patient preference. The study also illustrates the value of trials that reflect treatment-refractory clinical populations rather than only newly diagnosed patients.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
